Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF Best Seller
Catalog # 156-B7 | R&D Systems, Inc. a Bio-Techne Brand
Key Product Details
Source: | NS0 |
Accession #: | Q9NZQ7 |
Structure / Form: | Disulfide-linked homodimer |
Applications: | Bioactivity |
Citations for Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF (24)
Citations are publications that use Bio-Techne products. Selected citations for Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF include:
-
Species: Human
Sample Types: Cell Culture Supernates
Applications: ELISA CaptureCoulet et al. (2023-06-16), Identification of Small Molecules Affecting the Secretion of Therapeutic Antibodies with the Retention Using Selective Hook (RUSH) System Cells
PMID: 37371112 -
Species: Human
Sample Types: Whole Cells
Applications: BioassayO Munoz et al. (2022-07-05), Active PD-L1 incorporation within HIV virions functionally impairs T follicular helper cells PloS Pathogens, 2022-018(7):e1010673.
PMID: 35788752 -
Species: Human
Sample Types: Whole Cells
Applications: BioassayQ Gao et al. (2022-07-01), High mobility group protein B1 decreases surface localization of PD-1 to augment T-cell activation Cancer Immunology Research, 2022-00(0).
PMID: 35580259 -
Species: Human
Sample Types: Whole Cells
Applications: BioassayAP Curnock et al. (2021-10-22), Cell-targeted PD-1 agonists that mimic PD-L1 are potent T cell inhibitors JCI Insight, 2021-10(0).
PMID: 34491911 -
Species: Human
Sample Types: Whole Cells
Applications: BioassayN Bhaskaran et al. (2021-08-26), Oral immune dysfunction is associated with the expansion of FOXP3+PD-1+Amphiregulin+ T cells during HIV infection Nature Communications, 2021-012(1):5143.
PMID: 34446704 -
Species: Human
Sample Types: Reference Standard
CP Mao et al. (2021-08-11), Protein detection in blood with single-molecule imaging Science Advances, 2021-07(33).
PMID: 34380620 -
Species: Human
Sample Types: Recombinant Protein
Applications: BioassayM Ogishi et al. (2021-06-28), Inherited PD-1 deficiency underlies tuberculosis and autoimmunity in a child Nature Medicine, 2021-00(0).
PMID: 34183838 -
Species: Human
Sample Types: Whole Cells
Applications: BioassayC Vetrei et al. (2021-06-08), Immunomodulatory mAbs as Tools to Investigate on Cis-Interaction of PD-1/PD-L1 on Tumor Cells and to Set Up Methods for Early Screening of Safe and Potent Combinatorial Treatments Cancers, 2021-013(12).
PMID: 34201082 -
Species: Human
Sample Types: Whole Cells
Applications: BioassayJ Huetter et al. (2020-04-20), Characterization of BAY 1905254, an Immune Checkpoint Inhibitor Targeting the Immunoglobulin-Like Domain Containing Receptor 2 (ILDR2) Cancer Immunol Res, 2020-08(7):895-911.
PMID: 32312711 -
Species: Human
Sample Types: Whole Cells
Applications: BioassayL Sun et al. (2020-03-10), Targeting glycosylated PD-1 induces potent anti-tumor immunity Cancer Res., 2020-00(0).
PMID: 32156778 -
Species: Yeast, Yeast - Saccharomyces cerevisiae
Sample Types: Whole Cell
Applications: Binding AssayB Cembrola et al. (2019-12-28), Rapid Affinity Maturation of Novel Anti-PD-L1 Antibodies by a Fast Drop of the Antigen Concentration and FACS Selection of Yeast Libraries Biomed Res Int, 2019-12019(0):6051870.
PMID: 31976323 -
Species: Human
Sample Types: Whole Cells
Applications: BioassayKJ Carpenter et al. (2019-12-20), LXR-inverse agonism stimulates immune-mediated tumor destruction by enhancing CD8 T-cell activity in triple negative breast cancer Sci Rep, 2019-19(1):19530.
PMID: 31863071 -
Species: Human
Sample Types: Whole Cells
Applications: CAR-T (Bioassay)W Fu et al. (2019-09-25), CAR exosomes derived from effector CAR-T cells have potent antitumour effects and low toxicity Nat Commun, 2019-010(1):4355.
PMID: 31554797 -
Species: Human
Sample Types: Recombinant Protein
Applications: BioassayJK Fierle et al. (2019-09-06), Integrating SpyCatcher/SpyTag covalent fusion technology into phage display workflows for rapid antibody discovery Sci Rep, 2019-09(1):12815.
PMID: 31492910 -
Species: Human
Sample Types: Whole Cells
Applications: Flow CytometryA Osa et al. (2018-10-04), Clinical implications of monitoring nivolumab immunokinetics in non-small cell lung cancer patients JCI Insight, 2018-13(19).
PMID: 30282824 -
Applications: ELISA (Standard)UM Vogl et al. (2017-04-01), Evaluation of Prognostic Immune Signatures in Patients with Breast, Colorectal and Pancreatic Cancer Receiving Chemotherapy Anticancer Res., 2017-037(4):1947-1955.
PMID: 28373465 -
Sample Types: Protein
Applications: BioassayE Burova et al. (2017-03-06), Characterization of the anti-PD-1 antibody REGN2810 and its antitumor activity in human PD-1 knock-in mice Mol. Cancer Ther, 2017-00(0).
PMID: 28265006 -
Species: Human
Sample Types: Protein
Applications: ELISA (Standard)(2016-11-08), B7-H1 antibodies lose antitumor activity due to activation of p38 MAPK that leads to apoptosis of tumor-reactive CD8(+) T cells Sci Rep, 2016-16(0):36722.
PMID: 27824138 -
Applications: BioassayRobert L Ferris (2016-09-22), Tumor-infiltrating Tim-3(+) T cells proliferate avidly except when PD-1 is co-expressed: Evidence for intracellular cross talk Oncoimmunology, 2016-05(10):e1200778.
PMID: 27853635 -
Species: Human
Sample Types: Serum
Applications: ELISA (Standard)Melendreras S et al. (2014-12-05), Soluble co-signaling molecules predict long-term graft outcome in kidney-transplanted patients. PLoS ONE, 2014-19(12):e113396.
PMID: 25478957 -
Species: Human
Sample Types: Whole Cells
Applications: BioassayLi J et al. (2014-12-05), PD-1/SHP-2 inhibits Tc1/Th1 phenotypic responses and the activation of T cells in the tumor microenvironment. Cancer Res, 2014-175(3):508-18.
PMID: 25480946 -
Species: Human
Sample Types: Whole Cells
Applications: BioassayChinnadurai R et al. (2014-01-08), IDO-independent suppression of T cell effector function by IFN-gamma-licensed human mesenchymal stromal cells. J Immunol, 2014-0192(4):1491-501.
PMID: 24403533 -
Species: Human
Sample Types: Whole Cells
Applications: BioassaySteidl C et al. (2011-03-02), MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. Nature, 2011-0471(7338):377-81.
PMID: 21368758 -
Species: Human
Sample Types: N/A, Whole Cells
Applications: Bioassay, ELISA (Standard)Wan B et al. (2006-12-15), Aberrant regulation of synovial T cell activation by soluble costimulatory molecules in rheumatoid arthritis. J. Immunol., 2006-1177(12):8844-50.
PMID: 17142787
There are no citations that match your criteria.
Customer Reviews for Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF (21)
Customer Images
-
Application: Binding assay/Protein-protein interactionReason for Rating: Tested binding of PDL1-Fc w/ PD-1 using Octet. KD ~1.5uMVerified Customer | Posted 06/19/2020
-
Application: Binding assay/Protein-protein interactionVerified Customer | Posted 11/15/2019HEK cells expressing mCherry alone (LEFT) or hPD-1 mCherry (RIGHT) were incubated with 0.25 ug of hPD-L1 hIgG1. Binding was monitored by flow cytometry using an anti-human 488 secondary antibody.
-
Application: Stem/Immune cell maintenance or differentiationVerified Customer | Posted 12/06/2018
-
Application: Cell AdhesionVerified Customer | Posted 10/24/2018
-
Application: Enzymatic activity in vitroVerified Customer | Posted 10/12/2018
-
Application: CellProlifVerified Customer | Posted 09/28/2018
-
Application: Binding assay/Protein-protein interactionVerified Customer | Posted 08/26/2018
-
Application: SDS-PAGE ControlVerified Customer | Posted 04/12/2018
-
Application: Binding assay/Protein-protein interactionVerified Customer | Posted 03/30/2018
-
Application: SDS-PAGE ControlVerified Customer | Posted 03/15/2018
-
Application: SDS-PAGE ControlVerified Customer | Posted 03/11/2018
-
Application: Binding assay/Protein-protein interactionReason for Rating: Binding observed.Verified Customer | Posted 02/07/2018
-
Application: Binding assay/Protein-protein interactionVerified Customer | Posted 12/18/2017
-
Application: Binding assay/Protein-protein interactionVerified Customer | Posted 12/06/2017
-
Application: Binding assay/Protein-protein interactionVerified Customer | Posted 12/01/2017
-
Application: Binding assay/Protein-protein interactionVerified Customer | Posted 11/27/2017
-
Application: Binding assay/Protein-protein interactionVerified Customer | Posted 11/18/2017
-
Application: Binding assay/Protein-protein interactionVerified Customer | Posted 07/20/2017
-
Application: Cell AdhesionVerified Customer | Posted 07/20/2017
-
Application: SPR assayVerified Customer | Posted 07/14/2017SPR assay for Kinetics between PDL-1 and AntiPDL-1 Antibody
-
Verified Customer | Posted 05/23/2017Using Octet, we tested the ability of B7-H1/PD-L1 to bind recombinant PD-1 (R&D 8986-PD-100) and found them to specifically bind to each other.
There are no reviews that match your criteria.
FAQs for Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF
-
What is the pI (Isoelectric Point) of Recombinant Human PD-L1/B7-H1 Fc Chimera Protein (Catalog # 156-B7)?
The calculated pI for Recombinant Human PD-L1/B7-H1 Fc Chimera Protein (Catalog # 156-B7) is 7.1.
-
Do you have a human IgG1 Fc region that would be a suitable negative control for the linker sequence and Fc region in Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF (Catalog # 156-B7)?
Yes, we offer Recombinant Human IgG1 Fc Protein, CF (Catalog # 110-HG), which contains the human IgG Fc region and linker sequence.
-
Has Recombinant Human PD-L1/B7-H1 Fc Chimera Protein (Catalog # 156-B7), been evaluated on primary cells?
Bioactivity of Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF (Catalog # 156-B7) is evaluated by its ability to inhibit anti-CD3 antibody induced IL-2 secretion in human T lymphocyte primary cells. The ED50 for this effect is 0.075-0.75 μg/mL. We recommend reviewing our list of publications under the Citations tab on the product-specific web page to find reported use of our products in similar experimental layouts.
-
What are the differences between Recombinant Human PD-L1/B7-H1 His-tag Protein, CF (Catalog # 9049-B7) and Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF (Catalog # 156-B7)?
Recombinant Human PD-L1/B7-H1 Protein, CF (Catalog # 9049-B7) consists of (Phe19-Thr239) from Accession # Q9NZQ7. It has a His tag but no Fc chimera. Activity for 9049-B7 is measured in a binding assay with Recombinant Human PD‑1 Fc Chimera (Catalog # 1086-PD). Recombinant Human PD-L1/B7-H1 Fc Chimera Protein, CF (Catalog 156-B7) consists of the same region (Phe19-Thr239), but instead of a His tag, it has a linker region and an Fc chimera. Activity for 156-B7 is assessed in a cell-based assay measuring IL-2 production by human T lymphocytes.